IGF::OT::IGF - DEVELOPMENT OF MEDICAL COUNTERMEASURES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES, BASE, OPTION 1 AND OPTION 2 AWARD, 09/16/2013 - 09/15/2017

DEFINITIVE CONTRACT won by BIOCRYST PHARMACEUTICALS INC · work in DURHAM, NC
$47,755,723
RecipientBIOCRYST PHARMACEUTICALS INC UEI MGXADJ6SCLJ5
Award IDHHSN272201300017C
Award amount$47,755,723
Award typeDEFINITIVE CONTRACT
Awarding agencyDepartment of Health and Human Services — National Institutes of Health
NAICS541711 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY
PSCAN11
Set-asideUnrestricted
Start dateSep 16, 2013
End dateSep 30, 2022
Place of performanceDURHAM, NC
Record updatedSep 6, 2024

View the official award record

More awards won by BIOCRYST PHARMACEUTICALS INC

PERAMIVIR, RAPIVAB FLU TREATMENT
Department of Health and Human Services · $34,660,000 · Sep 1, 2018
PERAMIVIR (RAPIVAB 200MG/20ML (10MG/ML INJ SOLN))
Department of Health and Human Services · $13,877,674 · Sep 30, 2024
COVID-19. TO MANUFACTURE AND EVALUATE THE SAFETY, EFFICACY AND TOLERABILITY OF GALIDESIVIR A BROAD SPECTRUM, ANTIVIRAL THERAPEUTIC.
Department of Health and Human Services · $6,326,480 · Sep 1, 2020
BULK ORLADEYO PHARMACEUTICAL
Department of Veterans Affairs · $394,853 · Mar 12, 2025
BULK ORDER ORLADEYO
Department of Veterans Affairs · $385,448 · Mar 12, 2024

Our catalog shows awards with a value or ceiling of $250K+ active within the last 5 years. Need older history or smaller awards? Tell us what you need — we expand by request.

Awards tell you who won. Bids tell you what's next. BidCatch scans 100+ federal, state, and local sources every night and sends the new opportunities matching your trade — before they're awarded to someone else. $0 today for 14 days (card required), then $49.99/month.

Search open bids